JC, C., IA, S., VM, A., S, E., DJ, B., AS, B., . . . H, M. (2018). Chitosan-based nanoformulated (–)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Dove Medical Press.
Style de citation Chicago (17e éd.)JC, Chamcheu, et al. Chitosan-based Nanoformulated (–)-epigallocatechin-3-gallate (EGCG) Modulates Human Keratinocyte-induced Responses and Alleviates Imiquimod-induced Murine Psoriasiform Dermatitis. Dove Medical Press, 2018.
Style de citation MLA (8e éd.)JC, Chamcheu, et al. Chitosan-based Nanoformulated (–)-epigallocatechin-3-gallate (EGCG) Modulates Human Keratinocyte-induced Responses and Alleviates Imiquimod-induced Murine Psoriasiform Dermatitis. Dove Medical Press, 2018.